Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

Fig. 2

LS mean change from baseline in clinic spirometry measures (ITT population). LS mean (95% CI) change from baseline in clinic (a) trough FEV1 at Week 24, (b) FEV1 (L) at 3 h post dose at Week 24 and (c) trough FEV1 at Weeks 4, 12 and 24 (ITT population). Error bars represent 95% CI. ***p<0.001, treatment difference from placebo. CI, confidence interval; FEV1, forced expiratory volume in 1 s; ITT, intent-to-treat; LS, least squares; UMEC, umeclidinium; N, ITT population; n, number of participants with analysable data at Week 24

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us